Clinical Focus

• Cancer> Urologic Oncology
• Bladder Cancer
• Bladder Cancer - Medical Oncology
• Germ Cell Tumors
• Germ Cell Tumors - Medical Oncology

Administrative Appointments

• Prostate Panel member, NCCN (2002 - present)
• DSMC Vice Chair, Stanford University (2002 - present)

Honors and Awards

• Oncology Clinical Fellows Teaching award, Stanford University (2009)
• Oncology Clinical Fellows Teaching award, Stanford University (2008)
• Oncology Clinical Fellows teaching award, Stanford University (2007)
• Oncology Clinical Fellows Teaching award, Stanford University (2006)
• Oncology Clinical Fellows Teaching award, Stanford University (2005)

Professional Education

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Current Research Interests

The Genito-Urinary Multidisciplinary tumor board at Stanford specalizes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multisdiscplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored.Co-operative group particpation through ECOG is also available

Clinical Trials

• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT) Recruiting
• Phase I Sodium Selenite in Combination with Docetaxel in Castration-resistant Prostate Cancer Recruiting
• Phase II Itraconazole in CRPC Post Docetaxel Chemotherapy Recruiting
• Phase II Pazopanib in Combination with Weekly Paclitaxel in Refractory Urothelial Cancer Recruiting
• Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail) Recruiting

Publications

• NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, KumarR, Margolin KA, Michaelson D, Motzer RJ, Pili P, Roethke S, Srinivas S. J Natl Compr Canc Network. 2011: 9 29
• Pyoderma gangrenosum with the use of sunitinib. Nadauld LD, Miller MB, Srinivas S. J Clin Oncol. 2011; 29 (10): e266-7
• Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Harshman LC, Yu RJ, Allen GI, Srinivas S, Gill HS, Chung BI. Urol Oncol. 2011
• Toxicities of targeted agents in advanced renal cell carcinoma. Patel P, Srinivas S. Curr Clin Pharmacol. 2011; 6 (3): 181-8
• Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer Bazan JG, King CR, Brooks JD, Srinivas S. Open Prostate Cancer Journal. 2010: 3 99-104